Science Highlights
Published on November 13, 2026
MRD-Directed Therapy Prior to Autologous Transplantation
by Leukemia & Lymphoma
Yokoyama D, Minakata D, Fujiwara S-i, et al. MRD-Guided Induction-Intensification With Daratumumab-Carfilzomib-Based Regimen Followed by ASCT in Patients With Newly Diagnosed Multiple Myeloma. Leukemia & Lymphoma. 2026; (doi: 10.1080/10428194.2026.2723847).
Researchers see promise in a novel approach to induction intensification prior to autologous stem cell transplantation (ASCT) based on patients' measurable residual disease (MRD). The retrospective study included 60 patients with a new diagnosis of multiple myeloma who qualified for ASCT between 2020 and 2025. Most participants initially received bortezomib, lenalidomide, and dexamethasone as induction therapy, but patients with persistent MRD received treatment intensification, often with a combination of daratumumab, carfilzomib, and dexamethasone. MRD negativity was attained by 35 of 52 evaluable patients prior to transplant, and 30 of 32 patients evaluated after the procedure were MRD-negative. The findings demonstrated a robust response, with a 2-year progression-free survival rate of 87.3% and an overall survival rate of 98.0%. The study authors noted that patients with high-risk cytogenetics, including extramedullary disease, remain vulnerable to relapse and may benefit from a post-transplant intensification regimen.
Read more.